423 related articles for article (PubMed ID: 18682741)
1. A randomised controlled trial of triple antiplatelet therapy (aspirin, clopidogrel and dipyridamole) in the secondary prevention of stroke: safety, tolerability and feasibility.
Sprigg N; Gray LJ; England T; Willmot MR; Zhao L; Sare GM; Bath PM
PLoS One; 2008 Aug; 3(8):e2852. PubMed ID: 18682741
[TBL] [Abstract][Full Text] [Related]
2. Triple versus guideline antiplatelet therapy to prevent recurrence after acute ischaemic stroke or transient ischaemic attack: the TARDIS RCT.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Flaherty K; Duley L; England TJ; Havard D; Heptinstall S; James M; Kasonde C; Krishnan K; Markus HS; Montgomery AA; Pocock S; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N
Health Technol Assess; 2018 Aug; 22(48):1-76. PubMed ID: 30179153
[TBL] [Abstract][Full Text] [Related]
3. Antiplatelet therapy with aspirin, clopidogrel, and dipyridamole versus clopidogrel alone or aspirin and dipyridamole in patients with acute cerebral ischaemia (TARDIS): a randomised, open-label, phase 3 superiority trial.
Bath PM; Woodhouse LJ; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Flaherty K; Havard D; Heptinstall S; James M; Krishnan K; Markus HS; Montgomery AA; Pocock SJ; Randall M; Ranta A; Robinson TG; Scutt P; Venables GS; Sprigg N;
Lancet; 2018 Mar; 391(10123):850-859. PubMed ID: 29274727
[TBL] [Abstract][Full Text] [Related]
4. Clinical effectiveness and cost-effectiveness of clopidogrel and modified-release dipyridamole in the secondary prevention of occlusive vascular events: a systematic review and economic evaluation.
Jones L; Griffin S; Palmer S; Main C; Orton V; Sculpher M; Sudlow C; Henderson R; Hawkins N; Riemsma R
Health Technol Assess; 2004 Oct; 8(38):iii-iv, 1-196. PubMed ID: 15461876
[TBL] [Abstract][Full Text] [Related]
5. Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial.
Serebruany VL; Malinin AI; Pokov AN; Hanley DF
Clin Ther; 2008 Feb; 30(2):249-59. PubMed ID: 18343263
[TBL] [Abstract][Full Text] [Related]
6. Baseline characteristics of the 3096 patients recruited into the 'Triple Antiplatelets for Reducing Dependency after Ischemic Stroke' trial.
Bath PM; Appleton JP; Beridze M; Christensen H; Dineen RA; Duley L; England TJ; Heptinstall S; James M; Krishnan K; Markus HS; Pocock S; Ranta A; Robinson TG; Flaherty K; Scutt P; Venables GS; Woodhouse LJ; Sprigg N
Int J Stroke; 2017 Jul; 12(5):524-538. PubMed ID: 27811309
[TBL] [Abstract][Full Text] [Related]
7. Antiplatelet regimens in the long-term secondary prevention of transient ischaemic attack and ischaemic stroke: an updated network meta-analysis.
Niu PP; Guo ZN; Jin H; Xing YQ; Yang Y
BMJ Open; 2016 Mar; 6(3):e009013. PubMed ID: 26988347
[TBL] [Abstract][Full Text] [Related]
8. Antiplatelet Therapy After Noncardioembolic Stroke.
Greving JP; Diener HC; Reitsma JB; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Algra A
Stroke; 2019 Jul; 50(7):1812-1818. PubMed ID: 31177983
[TBL] [Abstract][Full Text] [Related]
9. Balancing Benefits and Risks of Long-Term Antiplatelet Therapy in Noncardioembolic Transient Ischemic Attack or Stroke.
Hilkens NA; Algra A; Diener HC; Bath PM; Csiba L; Hacke W; Kappelle LJ; Koudstaal PJ; Leys D; Mas JL; Sacco RL; Greving JP
Stroke; 2021 Oct; 52(10):3258-3265. PubMed ID: 34304604
[TBL] [Abstract][Full Text] [Related]
10. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (review of Technology Appraisal No. 90): a systematic review and economic analysis.
Greenhalgh J; Bagust A; Boland A; Martin Saborido C; Oyee J; Blundell M; Dundar Y; Dickson R; Proudlove C; Fisher M
Health Technol Assess; 2011 Sep; 15(31):1-178. PubMed ID: 21888837
[TBL] [Abstract][Full Text] [Related]
11. Prevention of secondary stroke and transient ischaemic attack with antiplatelet therapy: the role of the primary care physician [corrected].
Kirshner HS
Int J Clin Pract; 2007 Oct; 61(10):1739-48. PubMed ID: 17877660
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy for the prevention of recurrent stroke and other serious vascular events: a review of the clinical trial data and guidelines.
Hankey GJ
Curr Med Res Opin; 2007 Jun; 23(6):1453-62. PubMed ID: 17559741
[TBL] [Abstract][Full Text] [Related]
13. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
14. Review of antiplatelet therapy in secondary prevention of cerebrovascular events: a need for direct comparisons between antiplatelet agents.
Jamieson DG; Parekh A; Ezekowitz MD
J Cardiovasc Pharmacol Ther; 2005 Sep; 10(3):153-61. PubMed ID: 16211203
[TBL] [Abstract][Full Text] [Related]
15. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of antiplatelet agents for secondary prevention of stroke using mixed treatment comparison meta-analysis.
Malloy RJ; Kanaan AO; Silva MA; Donovan JL
Clin Ther; 2013 Oct; 35(10):1490-1500.e7. PubMed ID: 24139421
[TBL] [Abstract][Full Text] [Related]
17. Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (a fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in patients with strokes: the Prevention Regimen for Effectively Avoiding Second Strokes Trial (PRoFESS).
Diener HC; Sacco R; Yusuf S; ;
Cerebrovasc Dis; 2007; 23(5-6):368-80. PubMed ID: 17337887
[TBL] [Abstract][Full Text] [Related]
18. Antiplatelet therapy in ischemic stroke: variability in clinical trials and its impact on choosing the appropriate therapy.
Biller J
J Neurol Sci; 2009 Sep; 284(1-2):1-9. PubMed ID: 19380153
[TBL] [Abstract][Full Text] [Related]
19. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in Japan: a multicentre, open-label, randomised controlled trial.
Toyoda K; Uchiyama S; Yamaguchi T; Easton JD; Kimura K; Hoshino H; Sakai N; Okada Y; Tanaka K; Origasa H; Naritomi H; Houkin K; Yamaguchi K; Isobe M; Minematsu K;
Lancet Neurol; 2019 Jun; 18(6):539-548. PubMed ID: 31122494
[TBL] [Abstract][Full Text] [Related]
20. Dipyridamole for preventing stroke and other vascular events in patients with vascular disease.
De Schryver EL; Algra A; van Gijn J
Cochrane Database Syst Rev; 2003; (1):CD001820. PubMed ID: 12535415
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
